Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
The global pandemic created challenges the healthcare industry never could have imagined. However, it also opened the doors to innovation in trial conduct. For an industry that is cautious and modest in change, the pandemic accelerated the pace of innovation, adopting virtual technologies and digitization of processes in clinical research like never before.
One specific change is the adoption and rapid inclusion of remote and centralized monitoring and advanced analytics in lieu of more traditional on-site approaches. This change requires a level of expertise and experience that sponsors may not hold in-house and may consider use of a functional service provider, or FSP, to manage.
For more than a decade, regulatory bodies and other industry stakeholders have weighed in on the use of risk-based monitoring (RBM). The U.S. Food and Drug Administration and European Medicines Agency have provided guidance encouraging the use of centralized monitoring methods when appropriate.
Despite regulatory support, adoption of these models was slower than anticipated prior to the pandemic. However, we have witnessed tremendous advances in new clinical trial designs and technologies to mitigate against longstanding challenges to drug development.
Given lessons learned during the pandemic, sponsors may consider integrating technology and analytics across their portfolios moving forward, and how FSP experts may be able to help accomplish this.
Modernizing monitoring
Technology enablement is key to transforming trial monitoring in several ways, including automated key risk indicator (KRI) management, early signal detection across patient safety and eligibility, and fully auditable and traceable workflows to manage risks at the study, site and patient level.
If looking at modernizing monitoring in incremental levels, sponsors could see integration as:IQVIA’s FSP tech-enabled capabilities and breadth of data integration and analytics services allow sponsors to build a successful journey mapping through these three levels of operating model transformation. Implementation of decentralized and direct-to-patient process elements is driving demonstrable benefits in meeting patient recruitment needs for clinical research. In addition, the use of artificial intelligence and machine learning (AI/ML) capabilities enable monitoring of safety trends across sites, participants, or regions to make needed changes quickly.
In addition to clinical monitoring improvements, these methods can lower the total cost of clinical monitoring for a clinical trial by as much as 40%, and when adopted at scale across an enterprise, generate opportunity to invest those savings in more clinical research.
We now have a tangible example of how adversity can inspire innovation. If you wish to capitalize on the momentum for change and transform your clinical trial monitoring approaches, learn and co-discover with our experts as they share insights from more than a decade of experience in executing risk-based approaches to clinical trial monitoring across a full spectrum of outsourcing solutions (Staff Augmentation, FSP Outsourced, FSP Advance, End-to-End Full Service Delivery).
Please contact us directly to learn more about FSP capabilities and other outsourcing solutions specific to centralized monitoring or please visit globalFSPGTM@iqvia.com.
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Decrease clinical development costs and increase study quality using our global functional resources and flexible services, and get more value from your R&D spend.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.